10:36am Tuesday 12 December 2017

Weight management is critical for survival in motor neuron disease

The first UK wide study into tube feeding in MND (ProGas) has found that MND patients benefited most from enteral feeding when they had lost less than 10 per cent of their body weight before the intervention. In contrast, significant weight loss at the onset of enteral feeding was associated with shorter survival.

Based on the results of the study, published in the journal The Lancet Neurology, the investigators recommend enteral feeding for MND patients as early as possible at five per cent weight loss from MND diagnosis..

Chief Investigator Dr Chris McDermott, Reader in Neurology at SITraN and Consultant Neurologist at the MND Care and Research Centre at the Sheffield Teaching Hospitals NHS Trust, said:  “These findings will help health care professionals and patients to make informed decisions about the choice of gastrostomy method and timing.”

The prospective multi-centre evaluation of gastrostomy in patients with MND (ProGas) included data from 24 centres in the UK. A total of 330 patients in the study underwent gastrostomy which entails the insertion of a tube in the stomach to facilitate enteral feeding and were followed up for 12 months. The study aimed to provide evidence on the benefits and timing of gastrostomy feeding, as well as the optimum tube insertion method in terms of safety and clinical outcome.

Study author Dr Theocharis Stavroulakis, Research Associate at SITraN, who analysed the UK wide data said: “Although recommended by both the American Academy of Neurologists and European Federation of Neurological Societies, there was little evidence for the optimum method and timing for gastrostomy. Decisions in clinical practice are currently largely based on consensus and expert opinion. The aim of our study was to provide evidence for the available treatment options and establish guidelines for best clinical practice to improve care for MND patients.”

Enteral feeding is commonly used to support MND patients with severe difficulties in swallowing (dysphagia). The three main methods of gastrostomy currently used in MND patients are percutaneous endoscopic gastrostomy (PEG), radiologically inserted gastrostomy (RIG), and per-oral image-guided gastrostomy (PIG).

“The findings we present suggest that PEG might be the optimum method of gastrostomy when respiratory function is largely unimpaired, and PIG when respiratory function is significantly compromised,” said Dr Stavroulakis.

“Both methods seemed to offer easier post-insertion tube management than RIG. This is crucial in MND where loss of mobility and speech, as well as breathing problems can increase the burden on both patient and carer”.

The three gastrostomy methods were found to be as safe as each other with respect to procedural risk, however RIG was found to be associated with higher post-procedural complications associated with balloon-retention gastrostomy tubes and more complex tube management. PEG caused a higher rate of patient distress linked to procedure tolerance. There were no significant differences across the three methods in terms of survival or weight change. The study showed that delay of gastrostomy might lead to diminishing benefits, especially for patients who at the time of gastrostomy have experienced excessive weight loss from their diagnosis weight. The effect on the quality of life was perceived neutral by the participants, however the burden for the carer increased post-intervention.

The ProGas study was supported jointly by the Motor Neurone Disease Association of England, Wales and Northern Ireland and the Sheffield Institute for Translational Neuroscience at the University of Sheffield.

Director of Research at the UK MND Association Dr Brian Dickie said: “The results of this research will underpin the development of clinical guidelines to ensure greater consistency across MND clinics and improve the outcomes of gastrostomy for those affected by this devastating disease.

“Building on this evidence,” Dr McDermott said: “we now need to better understand the specific nutritional requirements of MND patients, particularly the quantity and quality of nutritional support that patients receive after gastrostomy.”

Reference:

The ProGas Study Group. Gastrostomy in patients with amyotrophic lateral sclerosis (ProGas): a prospective cohort study. The Lancet Neurology, published 29 May 2015 online
http://www.thelancet.com/journals/laneur/article/PIIS1474-4422(15)00104-0/abstract

Notes to editors:

The Motor Neurone Disease Association:

The MND Association was founded in 1979 by a group of volunteers with experience of living with or caring for someone with MND.

It is the only national charity in England, Wales and Northern Ireland focused on MND care, research and campaigning.

Motor Neurone Disease (MND), also known as Amyotrophic Lateral Sclerosis (ALS)

·      MND is a fatal, rapidly progressive disease that affects the brain and spinal cord.

·      It attacks the nerves that control movement so muscles refuse to work. Sensory nerves are not usually affected.

·      It can leave people locked in a failing body, unable to move, talk and eventually breathe.

·      It affects people from all communities.

·      It kills around 30% of people within a year of diagnosis, and more than 50% within two years.

·      It has no cure.
 

For more information visit: www.mndassociation.org

ProGas

For more information on the study, ProGas: A Prospective Multi-Centre Evaluation of Gastrostomy in Patients with Motor Neurone Disease, visit:http://sitran.dept.shef.ac.uk/clinical-studies/progas/

SITraN – The Sheffield Institute for Translational Neuroscience

SITraN is a world-leading research centre purpose-built and dedicated to research into motor neuron disease (MND/ALS) and related neurodegenerative diseases including Parkinson’s disease, Alzheimer’s disease, and stroke. The state-of-the art research facility was opened in 2010 by HM The Queen and uniquely allows the multidisciplinary collaboration of clinicians, scientists and health professionals to develop new treatments for the benefit of patients.

To find out more visit www.sheffield.ac.uk/sitran/

The University of Sheffield
With almost 26,000 of the brightest students from around 120 countries, learning alongside over 1,200 of the best academics from across the globe, the University of Sheffield is one of the world’s leading universities.

A member of the UK’s prestigious Russell Group of leading research-led institutions, Sheffield offers world-class teaching and research excellence across a wide range of disciplines.

Unified by the power of discovery and understanding, staff and students at the university are committed to finding new ways to transform the world we live in.

In 2014 it was voted number one university in the UK for Student Satisfaction by Times Higher Education and in the last decade has won four Queen’s Anniversary Prizes in recognition of the outstanding contribution to the United Kingdom’s intellectual, economic, cultural and social life.

Sheffield has five Nobel Prize winners among former staff and students and its alumni go on to hold positions of great responsibility and influence all over the world, making significant contributions in their chosen fields.

Global research partners and clients include Boeing, Rolls-Royce, Unilever, AstraZeneca, Glaxo SmithKline, Siemens and Airbus, as well as many UK and overseas government agencies and charitable foundations.

For further information, please visit www.sheffield.ac.uk


Share on:
or:

MORE FROM Brain Diseases

Health news